UPDATE: Keryx (KERX) Says KRX-0401 + Xeloda Did Not Meet Primary Endpoint in Phase 3
Tweet
Share
E-mail
Get Alerts KERX Hot Sheet
Join SI Premium – FREE
(Updated - April 2, 2012 7:06 AM EDT)
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reported today that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
This Phase 3 trial was conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. 468 patients at sixty-five U.S. sites participated in this study.
KRX-0401 (perifosine) is in-licensed by Keryx from AeternaZentaris Inc. (Nasdaq: AEZS) in the United States, Canada and Mexico.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reported today that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
This Phase 3 trial was conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. 468 patients at sixty-five U.S. sites participated in this study.
KRX-0401 (perifosine) is in-licensed by Keryx from AeternaZentaris Inc. (Nasdaq: AEZS) in the United States, Canada and Mexico.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Real and RE/MAX Holdings receive court approval for merger
- Hinge Health signs $86M office lease in San Francisco
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
